Idrx
Cambridge
About Idrx
Idrx is a clinical-stage biopharmaceutical that develops oncology-based precision therapies to treat gastrointestinal stromal tumors. It designs precision combination therapies, medicines with engineered drug combinations to stop key tumor escape mechanisms and prolong response to therapy.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Total funding: $242.0M
- Funding stage: M&A
- Last round: Series B (Aug 2024)
- Website: idrx.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Life Science, Oncology, Product Research
Social Profiles
Canonical: https://fsome.com/organization/idrx-23506 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.